You are not permitted to download, save or email this image. Visit image gallery to purchase the image.
The brokerage downgraded its recommendation on NZX-listed Comvita to "hold" from 'buy'.
New Zealand's largest natural health products company last month lowered its forecast for annual earnings, citing adverse weather in the second half of the 2018 honey season that cut volumes. That followed what it called an "extremely poor season" in 2017.
Comvita's shares had held up following the latest downgrade to earnings as investors waited to see if a merger went ahead. But the stock has fallen sharply since the company said on Monday that it had pulled out of the talks after failing to reach a deal on price.
That prompted investors and analysts to reassess the company's prospects.
"We continue to like the Comvita investment thematic, of becoming a more reliable premium branded manuka honey vertical targeting the Chinese consumer," Craigs research analyst Adrian Allbon said in his report.
However, he cut his outlook on the stock due to two consecutive short harvests materially impacting profitability and driving up debt.
Management needed to re-focus on core bee products to lift profitability, he said.
"Moreover, given the now two consecutive short harvests in a row, we also think it will be difficult for Comvita to deliver its sales target of NZ$400million by FY21, given a lower sales annuity and depressed profitability also restricting growth reinvestment.
"As a result, we now assume Comvita gets to NZ$400million by FY23."
Comvita expects after-tax operating earnings for the year ending June 30 to be $8million to $11million, down from an earlier forecast of more than $17.1million due to the poor honey harvest.
In its May 21 report, Craigs cut its 2018 net profit forecast to $7.5million from $18million and reduced its estimate for full-year sales to $180million from $220million. It also reduced its 12-month price target on the stock to $6.10 from $9.